The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
NCT Number: NCT07370805
This study aims to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET/CT in lung cancer.
Trial opening soon.
Get Notified20 year–85 year
All sexes
Observational
Hangzhou, Zhejiang, 310003, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1、Patients clinically suspected or confirmed with lung cancer are required to complete conventional imaging examinations (CT/MR or FDG PET) and undergo ¹⁸F-FAPI PET/CT.
Time frame: through study completion, an average of 1.5 year
Sensitivity, specificity, positive and negative predictive value of 18F-FAPI PET Imaging in lung cancer.
Time frame: through study completion, 3-4 years
This measure evaluates the association between baseline 18F-FAPI PET parameters (e.g., SUVmax, SUVmean).
Time frame: through study completion, 3-4 years
This measure evaluates the association between baseline 18F-FAPI PET parameters (MTV in cm3, TLG in cm3*SUV)
Time frame: through study completion, 3-4 years
PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model.(PFS in months)
Contact information is provided by the study sponsor or research team.
First Affiliated Hospital of Zhejiang University
Other
Prospective Clinical Study and Exploration of 18F-FAPI PET/CT Imaging in Lung Cancers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07728773
Disease, Dyspnea
Boston, Massachusetts, United States
View Trial DetailsNCT07662967
AI (Artificial Intelligence), Bronchoscopy
View Trial DetailsNCT07636148
Adenocarcinoma, Bone Cancer Metastatic
Lyon, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT07254650
Agnosia, Disease
Dallas, Texas, United States
View Trial Details